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Summary 
Patients with osteoarthritis (OA) of the knee were treated with chondroitin sulfate (CS, CondrosulP ~, IBSA, Lugano, 
CH) in a randomized, double-blind, placebo-controlled study, performed in two centres. 
The efficacy and tolerability of oral CS capsules 2• 400 mg/day vs placebo was assessed in a 6-month study period. 
Patients with idiopathic or clinically symptomatic knee OA, with Kellgren and Lawrence radiological scores I III, were 
included in this trial Clinical controls were performed at months 0, 1, 3 and 6. 
Eighty patients completed the 6-month treatment period. Lequesne's Index and spontaneous joint pain (VAS) 
decreased constantly in the CS group; on the contrary, slight variations of the scores were reported in the placebo 
group. The walking time, defined as the minimum time to perform a 20-meter walk, showed a statistically significant 
constant reduction only in the CS group. ANOVA with repeated measures showed a statistically significant difference 
in favor of the CS group for these three parameters. During the study, patients belonging to the placebo group reported 
a higher paracetamol consumption, but this consumption was not statistically different between the two treatment 
groups. Efficacy judgements were significant in favor of the CS group. Both treatments were very well tolerated. 
All these results strongly suggest hat chondroitin sulfate acts as a symptomatic slow-acting drug in knee OA. 
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Introduction 
THE SYMPTOMATIC osteoarthr it ic  knees could be 
treated either conservatively, including physical 
and pharmacologic possibilities, or surgically. For 
a long period of t ime the analgesics and the 
nonsteroidal  anti- inf lammatory agents were the 
only solution in the pharmacologic t reatment of 
these disorders, but due to recent developments 
the current concept is changing. According to 
Lequesne [1] the pharmacologic possibil ities in the 
t reatment of osteoarthr it ic  patients fall into three 
categories: 
1. Analgesics and non-steroidal anti-inflamma- 
tory agents; 
2. Symptomatic slow-acting drugs for osteoar- 
thrit is (SYSADOA); 
3. Chondroprotect ive or truly disease-modifying 
agents (not available as yet). 
The aim of this study was to determine, whether 
800 mg oral chondroit in sulfate (CS, Condrosult ~, 
IBSA, Lugano, CH) (SYSADOA), having been 
Supplement sponsored by IBSA (Switzerland)/Laboratoires 
GENEVRIER (France). 
given for 6 months, was effective in the t reatment 
of knee osteoarthrit is.  
Design of the study 
The study was designed to be a randomized 
double-blind, placebo-control led study involving 
two centers, to include at least 80 patients, 
suffering from knee osteoarthr it is  [2]. It was 
performed uring the period from September 1995 
to September 1996 in Hungary, Budapest. 
Patients and methods 
Hospital ized or out-patients with idiopathic or 
secondary cl inically symptomatic knee OA for 
more than 6 months, and showing upon entry 
Kel lgren and Lawrence radiological score I- I I I  
were enrol led in the study [2-3]. 
All patients suffering from other inf lammatory 
diseases or systemic condit ions affecting or 
possibly involving the joints as well as patients 
with secondary osteoarthr it is  of the knee joint 
were excluded from the study [3]. 
The chondroit in sulfate and the placebo were 
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Table I 
Patients' characteristics 
Group CS (n = 39) PBO (n = 46) P values 
Age (m _+ S.D.) 60.6 ___ 9.6 59.4 + 9.0 0.557* 
range 41 + 83 39 + 74 
Sex (M/F) 17/22 17/29 0.657t 
Weight in kg (m _+ S.D.) 83.4 _+ 13.9 80.2 _+ 16.1 0.343* 
range 57 + 115 51 + 110 
Height in cm (m _+ S.D.) 169 _+ 9 166 _+ 9 0.126" 
range 154 + 190 152 + 194 
*Student's t-test. 
tFisher exact test. 
administered in exact ly the same way, with the 
same dosage (800 mg/day) for a period of 6 months. 
The fol lowing cl inical evaluat ion parameters  
were recorded at entry and then at month 1, 3 and 
6 (end of the trial): 
9 Spontaneous jo int  pain was evaluated, consid- 
er ing pa in  dur ing physical  daily activity. The 
intensity of pain was judged by the pat ient  on a 
Visual  Analogue Scale (VAS) of 100 mm [4]; 
9 Paracetamol  consumption [5]. In case of pain, 
pat ients  were free to take paracetamol  if it was 
required. The consumpt ion was registered as total  
number  of tablets taken  during the study period. 
9 Locomotor  capacity,  measur ing the walk ing 
t ime [6]. The t ime required to take a 20-meter walk 
on flat ground was measured at each visit. 
9 Lequesne's Index, summariz ing the algofunc- 
t ional  parameters  concerning the pain, the 
maximal  walk ing distance, the discomfort in daily 
life movements  (score from 0 to 24), showing the 
exact pain evolut ion [5]. 
9 Global  efficacy and tolerabi l i ty judgement by 
pat ients  and by physic ians as well [7, 8]. The 
t reatment  global efficacy was judged at month 6 by 
the invest igator  and by the patient,  using a 4-point 
scale: excel lent = 3, good = 2, fair = 1, poor = 0. 
The stat ist ical  analysis of the results was 
performed by an independent Inst i tute of Biostatis- 
tics (IBIS In format ica  S.r.l., Milan, Italy) using 
BMDP Stat ist ical  Software. Analysis of var iance 
with repeated measures and mult iple compar isons 
according to Bonferroni  test was used for the 
parametr ic  variables. Nonparametr ic  var iables 
and var iables that  were not normal ly  distr ibuted 
were analyzed with the Mann-Whi tney  test, while 
the Pearson chi-square test was used for ana lyz ing 
the categor ical  type of variable.  In the case of 
tables 2x 2 the Fisher exact test was utilized. 
All the stat ist ical  tests were computed as 
two-tailed, and only results with P < 0.05 were 
considered as significant. 
Resu l ts  
PATIENTS' CHARACTERISTIC 
A total  of 85 patients, aged between 39 and 83, 
were included in the stat ist ical  analysis, and the 
rat io according to sex, age, body weight and size is 
shown in Table I. E ighty of them (36 chondroit in  
sulfate, CS/44 placebo, PBO) completed the 
6-month t reatment  period, while five pat ients  
(three CS + two PBO) dropped out after 3 months, 
three of them (two CS + one PBO) fai l ing to turn up 
for follow-up examinat ion;  one (CS) had severe 
viral  infection, and one (PBO) had brain tumor 
surgery, both not correlated to the treatment.  The 
two groups were stat ist ical ly homogeneous to 
Table II 
Kellgren and Lawrence radiological score 
X-ray score 
Femorotibial Femorotibial Femoropatellar Fem0ropatellar 
right (TR) left (TL) right (PR) left (PL) 
CS PBO CS PBO 
(n = 39) (n = 46) (n = 39) (n = 46) 
CS PBO CS PBO 
(n = 39) (n = 46) (n = 39) (n = 46) 
0 11 5 7 11 
I 10 12 10 10 
II 14 20 19 17 
III 4 9 3 8 
Chi-square test P-- 0.181 P = 0.438 
35 43 34 45 
2 2 2 1 
1 1 3 0 
1 0 0 0 
P = 0.740 P-- 0.115 
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Table III 
Distribution of affected knees 
CS PBO 
(n = 39) (n = 46) 
Monolateral 17 16 
Bilateral 22 30 
Fisher exact test: P-- 0.504. 
compare. The distr ibution of radiological score for 
femorotibial r ight (TR) or left (TL) and 
femoropatel lar r ight (PR) or left (PL) at baseline is 
listed in Table II. The homogeneity between 
treatment groups was confirmed by the chi-square 
test for each site analyzed (TR, TL, PR, PL). In 
addition, we arbitrar i ly calculated a total Kel lgren 
and Lawrence radiological score for each patient 
as follows. Total radiological score = radiological 
score (TR + TL + PR + PL). The total mean radio- 
logical score was 3.13 + 2.07 for the CS group and 
3.30 + 1.41 for the PBO group, respectively. 
The Mann-Whitney test was used to compare 
these mean values and no significant difference 
was observed between groups (P= 0.247). 
Also, the distr ibution of affected knees in 
monolateral  or bi lateral knee OA (Table III) did 
not show any statistical ly significant difference 
between the CS and PBO groups (Fisher exact test: 
P = 0.504). 
SPONTANEOUS JOINT PAIN (VAS) 
The degree of spontaneous joint pain measured 
with the Huskisson Visual Analogue Scale (VAS) 
[4] showed a constant significant reduct ion of 
spontaneous joint pain in the CS group, but not in 
the PBO one. The two groups were homogeneous 
at baseline (ANOVA: P=ns) .  After 1 month of 
treatment,  there was a 23% decrease of joint pain 
in the CS group as compared to 12% in the PBO 
group. This difference increased further at month 
3 with an overall  decrease in the CS group of 36% 
vs 7% in the PBO group. At the end of the study 
the reduct ion of joint pain was of 43% in the CS 
group vs 3% in the PBO group. The difference 
between both groups was statist ical ly significant 
in favor of the CS group from month 3 on (ANOVA 
with repeated measures and multiple comparisons 
according to Bonferroni  test: P < 0.01) (Table IV 
and Fig. 1). 
PARACETAMOL CONSUMPTION 
During the 6-month study, patients belonging to 
the placebo group reported a higher paracetamol 
consumption than those in the CS group, but the 
difference between groups at different times was 
not statist ical ly significant (Mann-Whitney test: 
P= ns). In Table IV the mean, median and range 
monthly paracetamol consumption is also 
reported. 
Since this pathology showed different symptoms 
according to the patient, a great variance in the 
paracetamol consumption was justified. 
LOCOMOTOR CAPACITY WALKING TIME 
The walking time, defined as the minimum time 
(sec) to perform a 20-metre walk on flat ground, 
showed a significant difference between the two 
groups in favor of the CS at month 6 and a 
statist ical ly significant constant reduct ion of 
walking time was reported only in the CS group. 
Table IV reports the results of the ANOVA with 
repeated measures and multiple comparisons 
according to Bonferroni  test. 
LEQUESNE'S INDEX 
The functional status of the patients in their 
daily lives was evaluated using Lequesne's Index 
[5]. This clinical study foresaw the inclusion of 
patients with mono- or bi lateral knee osteoar- 
thrit is and, if it was possible, the Lequesne's Index 
was arbitrar i ly evaluated for each affected knee, 
left or right, separately. To start with, the 
distr ibution of the scores for the Lequesne's 
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VAS, spontaneous joint pain (in mm). 
**P<0.01 (ANOVA with repeated measures and 
multiple comparisons according to Bonferroni test). 
9 =CS;  []  =PBO.  
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Table IV 
Efficacy results (mean values • S.D.) (CS: n = 39; PBO: n = 46) 
Control visits (months) 
Evaluation 
parameters 0 1 3 
VAS (mm) CS 56 • 17 43 • 195 
PBO 56 • 20 49 • 23 
Walking time (sec) CS 25.3 • 7.5 23.3 • 6.5 
PBO 25.1 ___ 8.3 24.8 • 8.2 
Lequesne's Index 
Left knee CS 12.0 • 3.7 10.2 • 4.05 
PBO 11.5 • 4.1 10.6 ___ 4.2 
Right knee CS 12.8 • 3.6 10.8 • 3.85 
PBO 11.8 • 3.9 10.9 • 3.8 
36 • 265 32 • 235 
52 • 24 55 • 26 
23.2 • 7.2t 22.5 • 6.85 
24.5 • 7.9 25.0 ___ 7.9 
9.0 + 4.55 7.6 • 4.25 
10.7 • 4.3 11.1 • 4.6 
9.9 • 4.65 8.1 • 4.75 
10.2 + 4.05 10.3 • 4.8 
Study period (months) 
{~1 1-3 3~3 
Monthly paracetamol 
consumption CS 
PBO 
Mean • S.D. 7.6 • 12.4 7.5 + 10.7 5.6 • 7.0 
Median 2 2.5 3 
Range 0 - 48 0 - 51 0 + 25 
Mean • S.D. 11.4 ___ 22.5 10.8 • 20.0 10.3 • 12.7 
Median 5 4.5 5.5 
Range 0 - 125 0 + 116 0 + 61 
ANOVA with repeated measures and multiple comparisons according to Bonferroni test: 
within group (basal vs control time): t = P < 0.05; :~P < 0.01 
between groups: *= P < 0.05; **P < 0.01 
The Mann-Whitney test between groups was utilized for the mean monthly paracetamol consumption. 
Index was homogeneous in the two groups with 
no statistical ly significant difference between 
groups (for left knees: 12 in the CS group vs 
11.5 in the PBO group; for r ight knees: 12.8 in 
the CS group vs 11.8 in the PBO group). In the CS 
group, the Lequesne's Index for both knees 
decreased constant ly by about 15, 24 and 37%, at 
month 1, 3 and 6, respectively. On the contrary, in 
the PBO group the Lequesne's Index showed slight 
variat ions of scores. ANOVA analysis was statisti- 
cally highly significant in favor of the CS group for 
both knees (Table IV and Figs 2 and 3). 
GLOBAL EFFICACY AND TOLERABILITY JUDGEMENT 
The subjective improvement score of efficacy 
judgement expressed by the physician after a 
6-month observation period was significantly in 
favor of the CS group (chi-square, P < 0.01). A total 
of 36% of the physician's judgements howed a 
global efficacy of the PBO treatment as nil vs 8% 
of the CS group. In addition, the physician's 
evaluat ion was in 26% of the cases in favor of the 
CS group 'very good' and in 43% 'good', while only 
9% of the physician's judgement concerning the 
PBO group reached 'very good' results and 23% 
showed 'good' results. The same criterion ex- 
pressed by the patients also showed a positive 
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FIG. 2. Lequesne's Index for left knees (mean values). 
*P < 0.05, **P < 0.01 (ANOVA with repeated measures 
and multiple comparisons according to Bonferroni test). 
- -0 - -  =CS;  [ ]  =PBO.  
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FIG. 3. Lequesne's Index for right knees (mean values). 
**P<0.01 (ANOVA with repeated measures and 
multiple comparisons according to Bonferroni test). 
- - i - -=  CS; - - [~- -  = PBO.  
trend for the CS group (chi-square, P < 0.01). At 
month 6, patients of the CS group expressed 26% 
very good results, 40% good results and 23% 
fair results, and 11% reported an absence of 
improvement. In contrast, the PBO patients 
expressed 18% of excellent results, 14% good 
results and 29% fair results, but an absence of 
improvement was found in 39% of patients 
(Table V). 
The overall tolerability judgement of the test 
drug expressed both by the physician and the 
patients was excellent. Only one patient of 
the PBO group complained of flight gastro- 
intestinal symptoms after 1 month, probably 
correlated to the treatment. The comparison 
between both groups after a 6-months treatment 
period did not show any significant difference in 
terms of clinical side-effects. In addition, the 
biological tolerability was also excellent in both 
groups. 
Conc lus ions  
This 6-month randomized, ouble-blind, placebo- 
controlled-study, involving two centers, including 
85 patients of both sexes, aged 39-83 years, 
suffering from knee osteoarthritis, was designed to 
evaluate the clinical efficacy and tolerability of the 
oral administration of 800 mg chondroitin sulfate. 
The functional status of the patients in their daily 
life was evaluated using the Lequesne's Index. In 
the chondroitin sulfate group, the Lequesne's 
Index decreased constantly by about 15, 24 and 
37%, at month 1, 3 and 6, respectively. On the 
contrary, in the placebo group the Lequesne's 
Index showed slight variations of the scores. Also, 
the walking time, defined as the minimum time 
(sec) to perform a 20-meter walk on flatground, 
showed a constant reduction of time only in the 
CS-group. Both parameters proved the improve- 
ment of joint mobility in the CS group. 
Considering the remission of the joint pain 
measured with the VAS (Huskisson Visual Ana- 
logue Scale) in the CS group, the lower paraceta- 
mol consumption i  this group and the excellent 
tolerability of the chondroitin sulfate, we may 
affirm that CS can safely alleviate OA symptoms 
showing an antalgic activity. The very good 
tolerability of CS is of great importance, specially 
when dealing with chronic clinical states such as 
osteoarthritis which require prolonged treatments 
or at least periodic treatment cycles. 
Even if the aim of this clinical trial was just to 
prove the efficacy of CS in patients suffering 
from knee OA, were calculated the statistic again 
twice: 
9 by considering the x-ray severity of patients at 
inclusion time. 
9 by dividing patients in monolateral or bilateral 
knee OA. 
Neither of these two statistical results differed 
from those obtained with the intention-to-treat 
analysis as reported above. 
Groups 
PBO 
CS 
Chi-square test 
Table V 
Global efficacy judgments (%) 
Physician Patient 
Very good Good Fair Poor Very good Good Fair Poor 
9 23 32 36 18 14 29 39 
26 43 23 8 26 40 23 11 
P< 0.01 P < 0.01 
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In conclusion, the following effects are proven 
by this study concerning the chondroitin sulfate 
CS vs placebo PBO: 
9 CS was able to reduce pain significantly; 
9 CS reduced the walking time significantly; 
9 CS reduced the Lequesne's Index significantly; 
9 There was a significantly positive global 
efficacy judgement for CS; 
9 The overall tolerability judgement was 
excellent. 
The final results of this study demonstrate that 
chondroitin sulfate given orally for 6 months at a 
dosage of 800mg/day is an effective and safe 
symptomatic slow-acting drug (SYSADOA) in 
patients suffering from knee osteoarthritis, and 
that its efficacy seemed to be independent from the 
x-ray severity of the pathology and its location 
(monolateral or bilateral). 
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